Hepatorenales Syndrom

Glossar

EABV = effektives arterielles Blutvolumen

HRS = hepatorenales Syndrom

TIPS = transjugulärer intrahepatischer portosystemischer Shunt

Literatur

• 1 Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial.  Gastroenterology. 2000;  119 1637-1648
• 2 Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, Amodio P, Sticca A, Caregaro L, Maffei-Faccioli A, Gatta A. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.  Hepatology. 1999;  29 1690-1697
• 3 Arroyo V, Gines P, Gerbes A L, Dudley F, Gentilini P, Laffi G, Reynolds T B, Ring-Larsen H, Schölmerich J. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis.  Hepatology. 1996;  23 164-176
• 4 Brensing K A, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, Klehr H U, Kramer H J, Spengler U, Schild H, Sauerbruch T. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study.  Gut. 2000;  47 288-295
• 5 Ginès A, Escorsell A, Ginès P. et al . Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites.  Gastroenterology. 1993;  105 229-236
• 6 Gonwa T A, Klintmalm G B, Levy M, Jennings L S, Goldstein R M, Husberg B S. Impact of pretransplant renal function on survival after liver transplantation.  Transplantation. 1995;  59 361-365
• 7 Gülberg V, Bilzer M, Gerbes A L. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine.  Hepatology. 1999;  30 870-875
• 8 Gülberg V, Gerbes A L. TIPS or Vasoconstrictors for the Treatment of Hepatorenal Syndrome Type 1 - Effect on Survival?.  Z Gastroenterol. 2002;  40 823-826
• 9 Heemann U, Treichel U, Loock J, Philipp T, Gerken G, Malago M, Klammt S, Loehr M, Liebe S, Mitzner S, Schmidt R, Stange J. Albumin dialysis in cirrhosis with superimposed acute liver injury: A prospective, controlled study.  Hepatology. 2002;  36 949-958
• 10 Kamath P. Is there life in MARS?.  Hepatology. 2002;  36 1017-1019
• 11 Lenz K, Hörtnagl H, Druml W, Reither H, Schmid R, Schneeweiss B, Laggner A, Grimm G, Gerbes A L. Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis: Effects on renal hemodynamics and atrial natriuretic factor.  Gastroenterology. 1991;  101 1060-1067
• 12 Moreau R, Durand F, Poynard T. et al . Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study.  Gastroenterology. 2002;  122 923-930
• 13 Schrier R W, Arroyo V, Bernardi M, Epstein M, Henriksen J H, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.  Hepatology. 1988;  8 1151-1157
• 14 Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, Castells L, Vargas V, Soriano G, Guevara M, Gines P, Rodes J. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.  N Engl J Med. 1999;  341 403-409
• 15 Uriz J, Ginès P, Cárdenas A, Sort P, Jiménez W, Salmerón J M, Bataller R, Mas A, Navasa M, Arroyo V, Rodés J. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome.  J Hepatol. 2000;  33 43-48
• 16 Wong F, Blendis L. New challenge of hepatorenal syndrome: prevention and treatment.  Hepatology. 2001;  34 1242-1251